Dare Bioscience vs Vistagen Therapeutics
Vistagen Therapeutics reported revenue of $1 million in fiscal 2026, 1.3 times Dare Bioscience's $1 million in fiscal 2025. Dare Bioscience's revenue grew 10429.4% in its latest year, and Vistagen Therapeutics' grew 161.1%. Dare Bioscience had an operating margin of -1315.5%, against -5683.7% at Vistagen Therapeutics. Their fiscal years end in different months (December 31 and March 31), so the periods don't line up exactly.
Side by side
| Dare Bioscience | Vistagen Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2026, Mar 31, 2026 |
| Revenue | $1M | $1M |
| Revenue growth | 10,429.4% | 161.1% |
| Revenue growth a year, last 5 years | — | 3.4% |
| Gross margin | 71.3% | — |
| Operating margin | −1,315.5% | −5,683.7% |
| Net margin | −1,300.7% | −5,491.3% |
| Free cash flow | −$10M | — |
| Free cash flow margin | −997.0% | — |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 31.6% | 23.3% |
| Last close | $0.45 | $0.19 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | — | 2 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Dare BioscienceVistagen Therapeutics
Operating margin
Percent of revenue
Dare BioscienceVistagen Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Dare BioscienceVistagen Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Dare Bioscience and Vistagen Therapeutics pages.